TR200103759T2 - Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı - Google Patents

Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı

Info

Publication number
TR200103759T2
TR200103759T2 TR2001/03759T TR200103759T TR200103759T2 TR 200103759 T2 TR200103759 T2 TR 200103759T2 TR 2001/03759 T TR2001/03759 T TR 2001/03759T TR 200103759 T TR200103759 T TR 200103759T TR 200103759 T2 TR200103759 T2 TR 200103759T2
Authority
TR
Turkey
Prior art keywords
disorders
norcisapride
bulimia
optically pure
apnea
Prior art date
Application number
TR2001/03759T
Other languages
English (en)
Inventor
D. Rubin Paul
J. Barberich Timothy
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Publication of TR200103759T2 publication Critical patent/TR200103759T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Apne, apne bozukluklari, bulimia nervosa, tahrisat yaratabilen bagirsak sendromu, idrarini tutamama, bradikardi, bradiaritmi, sinkop, baska bozukluklar ya da bunlarin semptomlarinin engellenmesi ya da kontrol altina alinmasi için, esas olarak (+) stereoizomerini barindirmayan (-) norsisaprid ya da farmasötik açidan kabul edilebilir bir tuzunun kullanimi.
TR2001/03759T 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı TR200103759T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8922598P 1998-06-15 1998-06-15
US12223699P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
TR200103759T2 true TR200103759T2 (tr) 2002-06-21

Family

ID=26780367

Family Applications (6)

Application Number Title Priority Date Filing Date
TR2001/03759T TR200103759T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
TR2000/03707T TR200003707T2 (tr) 1998-06-15 1999-06-10 Apne , bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
TR2001/03760T TR200103760T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
TR2001/03762T TR200103762T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı.
TR2001/03757T TR200103757T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
TR2001/03758T TR200103758T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı.

Family Applications After (5)

Application Number Title Priority Date Filing Date
TR2000/03707T TR200003707T2 (tr) 1998-06-15 1999-06-10 Apne , bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
TR2001/03760T TR200103760T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
TR2001/03762T TR200103762T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı.
TR2001/03757T TR200103757T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
TR2001/03758T TR200103758T2 (tr) 1998-06-15 1999-06-10 Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı.

Country Status (24)

Country Link
US (2) US6559165B1 (tr)
EP (1) EP1087765B1 (tr)
JP (1) JP2003522103A (tr)
KR (3) KR20060067985A (tr)
CN (1) CN1312716A (tr)
AR (1) AR020327A1 (tr)
AT (1) ATE291916T1 (tr)
AU (1) AU764474B2 (tr)
BG (1) BG105097A (tr)
BR (1) BR9911302A (tr)
CA (1) CA2334369A1 (tr)
CZ (1) CZ20004736A3 (tr)
DE (1) DE69924488T2 (tr)
ES (1) ES2237117T3 (tr)
HK (1) HK1040059A1 (tr)
HU (1) HUP0102026A3 (tr)
IL (1) IL140117A0 (tr)
IS (1) IS5755A (tr)
NO (1) NO20006358L (tr)
NZ (3) NZ535055A (tr)
PL (1) PL345325A1 (tr)
SK (1) SK19062000A3 (tr)
TR (6) TR200103759T2 (tr)
WO (1) WO1999065490A2 (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6663639B1 (en) 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US8287554B2 (en) 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
CA2590802A1 (en) 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4598123A (en) 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5116407A (en) 1988-10-13 1992-05-26 Courtaulds Coatings Limited Antifouling coatings
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
JPH02188523A (ja) 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
ATE170747T1 (de) * 1991-12-21 1998-09-15 Smithkline Beecham Plc Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2139638A1 (en) 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
AU4770593A (en) 1992-07-07 1994-01-31 Sepracor, Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
WO1995001803A1 (en) 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations
US5502067A (en) 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
US5407953A (en) 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
BR9811676A (pt) * 1997-07-11 2000-09-19 Janssen Pharmaceutica Nv (+) norcisaprida útil para distúrbios mediados por 5-ht3 e 5-ht4
IL140118A0 (en) 1998-06-15 2002-02-10 Sepracor Inc Use of optically pure (+) norcisapride for treating apnea, bulimia and other disorders

Also Published As

Publication number Publication date
NZ535055A (en) 2006-04-28
US7064138B2 (en) 2006-06-20
BR9911302A (pt) 2001-03-13
TR200103758T2 (tr) 2002-06-21
DE69924488D1 (de) 2005-05-04
US6559165B1 (en) 2003-05-06
BG105097A (en) 2002-02-28
JP2003522103A (ja) 2003-07-22
HK1040059A1 (zh) 2002-05-24
WO1999065490A3 (en) 2000-04-13
TR200103760T2 (tr) 2002-06-21
ES2237117T3 (es) 2005-07-16
CN1312716A (zh) 2001-09-12
NZ526108A (en) 2004-10-29
KR20010052740A (ko) 2001-06-25
PL345325A1 (en) 2001-12-17
TR200103762T2 (tr) 2002-05-21
IS5755A (is) 2000-12-08
IL140117A0 (en) 2002-02-10
CZ20004736A3 (cs) 2001-09-12
CA2334369A1 (en) 1999-12-23
US20030158229A1 (en) 2003-08-21
AU764474B2 (en) 2003-08-21
DE69924488T2 (de) 2005-09-08
NZ508825A (en) 2003-09-26
AR020327A1 (es) 2002-05-08
HUP0102026A3 (en) 2002-12-28
EP1087765A2 (en) 2001-04-04
TR200103757T2 (tr) 2002-06-21
EP1087765B1 (en) 2005-03-30
TR200003707T2 (tr) 2001-06-21
WO1999065490A2 (en) 1999-12-23
NO20006358L (no) 2001-02-13
HUP0102026A2 (hu) 2001-11-28
KR20060067985A (ko) 2006-06-20
AU4678499A (en) 2000-01-05
NO20006358D0 (no) 2000-12-13
SK19062000A3 (sk) 2001-07-10
ATE291916T1 (de) 2005-04-15
KR20060020739A (ko) 2006-03-06

Similar Documents

Publication Publication Date Title
TR200003708T2 (tr) Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı.
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
EP1140840A4 (en) -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS
NO20082823L (no) Spirosykliske forbindelser som HDAC-innhibitorer
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
HRP20020748A2 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
SE9800836D0 (sv) New Compounds
ATE309194T1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
TR200100805T2 (tr) Tetrahidropiridoeterler
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
TR200200928T2 (tr) 2-pirazolin-5-on terkipleri
TR200103757T2 (tr) Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
Ma et al. Mechanisms of melatonin in anti-aging and its regulation effects in radiation-induced premature senescence
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
Silveira et al. Pharmacological inhibition of UPR sensor PERK attenuates HIV Tat‐induced inflammatory M1 phenotype in microglial cells
BR0314783A (pt) Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias
NO20020914L (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
WO2001008668A3 (en) Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
MX2007002583A (es) Metodos y composiciones para realzar la degradacion de factores de transcripcion del receptor nuclear y sus usos.
EA200500865A1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол